Max Robotics — Global Service Robot Directory + US Certification

About

Dr. Michael Leapman is a urologic oncologist and health services researcher whose work centers on improving prostate cancer care through surgical innovation, health equity, and environmental health. His landmark study on decisional regret after robotic-assisted laparoscopic prostatectomy revealed that African American men experience significantly higher regret rates (36 citations), highlighting critical disparities in surgical counseling and outcomes. Dr. Leapman has also pioneered research at the intersection of climate change and urology, authoring one of the first papers to link environmental shifts to urological disease patterns (16 citations). His surgical expertise is demonstrated through novel applications of robotic techniques, including the first reported robotic excision of congenital mega-seminal vesicle in Zinner’s syndrome (8 citations) and adaptations for patients with prior proctocolectomy (4 citations). Dr. Leapman’s investigations into metabolic syndrome’s impact on prostatectomy outcomes (16 citations) and statin effects on PSA dynamics (4 citations) have informed preoperative risk stratification. His recent work on single-port transvesical robotic prostatectomy (2 citations) represents the frontier of minimally invasive surgery, aiming to accelerate continence and erectile function recovery. Through his dual focus on technical excellence and health equity, Dr. Leapman is reshaping how urologists approach prostate cancer treatment across diverse populations.